NASDAQ$VIR
Vir Biotechnology Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported a net loss for the second quarter of 2022 and provided a corporate update
Vir Biotechnology reported a net loss of $76.5 million for the second quarter of 2022, with revenues totaling ($40.6 million). The company is shifting its strategy to focus on long-term control of COVID-19 and advancing its pipeline in hepatitis B, hepatitis D, and influenza A. Vir's cash, cash equivalents, investments, and profit-share payments from GSK are expected to fund operations for up to five years.
- Vir closed the second quarter with sufficient funds to operate for up to five years.
- The company is shifting its COVID-19 strategy to focus on long-term control.
- Multiple Phase 2 and Phase 3 data readouts are expected from programs in COVID-19, hepatitis B, hepatitis D and influenza A.
- The company expects multiple milestones in the second half of 2022, including trial initiations and data readouts.
Headline financials
Revenue & EPS history
Vir · Revenue · Quarterly
-$40.6M
Revenue by segment
Vir · -$52.9M total across 2 segments · Q2 2022
- Grant revenue$2.06M-33.6%-3.9%
- License & collaboration revenue-$54.9M-1136.6%103.9%
Forward guidance
Vir Biotechnology anticipates several milestones in the second half of 2022, including the initiation of a Phase 2 trial for universal prophylaxis for influenza A, the first trial in hepatitis D, and multiple data readouts from hepatitis B and HIV programs.
Tailwinds
- Initiation of a Phase 2 trial for universal prophylaxis for influenza A.
- Initiation of the first trial in hepatitis D.
- Multiple data readouts from hepatitis B programs.
- Additional safety data from the Phase 1b portion of the trial are expected in the second half of 2022.
- Additional HBV milestones expected in 2022.
Headwinds
- The Company and GSK do not plan to file a Biologics License Application for sotrovimab at this time and do not intend to pursue the US-based Phase 3 COMET-STAR prophylaxis trial.
- Due to the continued proportion of COVID-19 cases caused by certain Omicron subvariants, sotrovimab is not currently authorized in any US region.
- There are limited clinical data available for sotrovimab.
- Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19.
- SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
+2.0%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-1.3%
Avg return
30 days after
43%
12 / 28 earnings
Positive
+27.7%
Q4 2025
Best reaction
-15.1%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.8% | -7.2% | -13.7% | |
| Q4 2025 | +27.7% | +22.3% | +20.6% | |
| Q3 2025 | -5.6% | -8.9% | +8.3% | |
| Q1 2025 | -3.4% | -16.2% | -2.9% | |
| Q4 2024 | -11.8% | -10.9% | -27.2% | |
| Q3 2024 | +21.8% | +26.8% | +4.7% | |
| Q2 2024 | -9.4% | -15.4% | -18.7% | |
| Q1 2024 | +18.9% | +13.6% | +17.5% | |
| Q4 2023 | +14.0% | +13.1% | -0.6% | |
| Q3 2023 | +12.5% | +8.3% | +24.4% | |
| Q2 2023 | -3.0% | -4.8% | -10.9% | |
| Q1 2023 | -3.5% | -4.5% | +7.5% | |
| Q4 2022 | -14.8% | -15.6% | -16.7% | |
| Q3 2022 | +15.0% | +20.3% | +23.7% | |
| Q2 2022 | +2.0% | -4.9% | -25.9% | |
| Q1 2022 | -3.1% | -1.4% | +12.5% | |
| Q4 2021 | +0.1% | -13.7% | -21.5% | |
| Q3 2021 | -15.1% | -11.7% | +20.4% | |
| Q2 2021 | +3.3% | +10.5% | +32.0% | |
| Q1 2021 | -1.0% | -8.5% | +3.5% | |
| Q4 2020 | -4.2% | -11.7% | -21.2% | |
| Q3 2020 | +8.2% | +5.8% | +26.0% | |
| Q2 2020 | -0.6% | -0.9% | -46.8% | |
| Q2 2019 | -0.6% | -0.9% | -46.8% | |
| Q1 2020 | -1.9% | -3.1% | +7.2% | |
| Q1 2019 | -1.9% | -3.1% | +7.2% | |
| Q4 2019 | +11.5% | +11.4% | +6.0% | |
| Q3 2019 | -3.0% | -0.5% | -3.7% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro